Physician profile
Arun Jesudian
NPI 1265699821
$827,981.62
in general payments reported to CMS, 2019-2025
18 companies · $261K in 2025
The $261K reported for 2025 was more than what 99% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $39K · 2021: $52K · 2022: $111K · 2023: $113K · 2024: $159K · 2025: $261K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $254K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $132K · Consulting Fee: $83K · Travel and Lodging: $49K · Food and Beverage: $14K · Grant: $1,719 · Entertainment: $15.23 · Education: $10.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $253,773.56 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $131,556.25 |
| Consulting Fee | $82,986.26 |
| Travel and Lodging | $48,524.63 |
| Food and Beverage | $13,862.49 |
| Grant | $1,718.75 |
| Entertainment | $15.23 |
| Education | $10.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $527,650.74 | 2019-2025 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $136,918.69 | 2022-2025 | Terlivaz |
| Dynavax Technologies Corporation | $74,272.09 | 2020-2025 | Heplisav-B |
| Madrigal Pharmaceuticals | $54,401.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $13,484.01 | 2024-2025 | Wegovy |
| Gilead Sciences, INC. | $5,730.91 | 2020-2025 | Livdelzi |
| Bard Peripheral Vascular, INC. | $5,355.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $4,582.13 | 2025 | Iqirvo |
| Spectrum Pharmaceuticals INC. | $2,620.00 | 2025 | Rolvedon |
| Grifols Therapeutics LLC | $2,050.00 | 2023 | Albutein |
| Zoll Medical Corporation | $375.00 | 2022 | |
| Mirum Pharmaceuticals, INC. | $188.41 | 2025 | Livmarli |
| Grifols, S.A. | $118.25 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.70 | 2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $82.46 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $19.26 | 2024 | Cuvrior |
| Stereotaxis INC | $15.23 | 2025 | Genesis |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Jesudian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.